JP6416001B2 - N,n’−ジアセチルキトビオースデアセチラーゼ阻害剤及び新規化合物 - Google Patents
N,n’−ジアセチルキトビオースデアセチラーゼ阻害剤及び新規化合物 Download PDFInfo
- Publication number
- JP6416001B2 JP6416001B2 JP2015015146A JP2015015146A JP6416001B2 JP 6416001 B2 JP6416001 B2 JP 6416001B2 JP 2015015146 A JP2015015146 A JP 2015015146A JP 2015015146 A JP2015015146 A JP 2015015146A JP 6416001 B2 JP6416001 B2 JP 6416001B2
- Authority
- JP
- Japan
- Prior art keywords
- dac
- compound
- group
- formula
- deacetylase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 10
- CDOJPCSDOXYJJF-KSKNGZLJSA-N N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CDOJPCSDOXYJJF-KSKNGZLJSA-N 0.000 title claims description 9
- CDOJPCSDOXYJJF-UHFFFAOYSA-N UNPD21501 Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(NC(C)=O)C(O)C(O)C(CO)O1 CDOJPCSDOXYJJF-UHFFFAOYSA-N 0.000 title claims description 9
- 229940122964 Deacetylase inhibitor Drugs 0.000 title claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 229910052744 lithium Inorganic materials 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 229910052708 sodium Inorganic materials 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 229940125904 compound 1 Drugs 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- -1 etc.) Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 241000205156 Pyrococcus furiosus Species 0.000 description 2
- 241000522615 Pyrococcus horikoshii Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229940123982 Cell wall synthesis inhibitor Drugs 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
項1. 下記式(I)
で表されるN,N’-ジアセチルキトビオースデアセチラーゼ阻害剤
項2. 下記式(Ia)
で表わされる化合物。
化合物(1)と化合物(2)を溶媒中で、必要に応じて塩基の存在下に室温から溶媒の沸騰する温度で1〜24時間反応させることで、反応は有利に進行する。
(1)化合物1(式(Ia)において、M=Naの化合物)のデザイン
一般にアシル基の加水分解反応は正四面体型のオキシアニオン中間体を経由する。Ph-Dacの立体構造を明らかにする先行研究において、我々は結晶化溶液中に含まれるリン酸イオンがPh-Dacの活性中心に結合している様子を観測した。そのことから、本来のオキシアニオン中間体の炭素原子をリン原子に置換し、リン原子が四面体構造をとって4個の原子と共有結合し、それらの原子のうち2個が酸素である、という条件を満たせば基質アナログ・中間体アナログとしてDacの結成部位に結合する分子を設計できると予想した。その予想に基づき、化合物1を設計・合成した。
化合物1の1H-NMR(in D2O)を図3に示す。
タンパク質溶液(a)とリザーバー液(b)を1マイクロリットルずつ混和し、リザーバー液(b)400マイクロリットルに対して20℃で2〜3日間蒸気拡散し、結晶を得た。得られた結晶を抗凍結剤(c)に数秒間浸漬したのち冷却窒素ガスで凍結し、X線を照射してデータを得た。そのデータを計算することによって、下記(3)に示すようにPh-Dacと化合物1の複合体の立体構造を明らかにした。
(b) 0.6 M ammonium phosphate monobasic (NH4H2PO4)
(c) 0.4 M ammonium phosphate monobasic (NH4H2PO4), 35% グリセロール, 1 mM 化合物1
以下の組み合わせで相互作用(水素結合)が観測された。
Ph-DacのArg92 ――― 化合物1の3位ヒドロキシ基
Ph-DacのArg92 ――― 化合物1の4位ヒドロキシ基
Ph-DacのAsp115 ――― 化合物1の4位ヒドロキシ基
Ph-DacのAsp115 ――― 化合物1の5位ヒドロキシ基
Ph-DacのHis152 ――― 化合物1の6位ヒドロキシ基
(図1では見えないが)リンに結合している2個の酸素が活性中心の亜鉛に配位している。
酵素反応液を(d)25℃で保温し、様々な反応時間ごと(酵素反応液にN-アセチルグルコサミンを入れてからの時間)に一部を取り出し、0.1 N HClで10倍希釈して反応を停止した。希釈した液を分光光度計で紫外吸収を測定し、215 nmにおける吸光度を反応時間に対してプロットした。
215 nmにおける吸光度は-NH-CO-グループの吸収に由来し、N-アセチル基が加水分解されるとその吸光が減少する(図2)。化合物1を含まない酵素反応系では脱アセチル化反応の進行が観測されたのに対して、化合物1を1 mM含む系では吸光度が変化しなかった。これは脱アセチル化反応が進行しなかったことを示す。
Claims (2)
- 下記式(I)
で表されるN,N'-ジアセチルキトビオースデアセチラーゼ阻害剤。 - 下記式(Ia)
で表わされる化合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015015146A JP6416001B2 (ja) | 2015-01-29 | 2015-01-29 | N,n’−ジアセチルキトビオースデアセチラーゼ阻害剤及び新規化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015015146A JP6416001B2 (ja) | 2015-01-29 | 2015-01-29 | N,n’−ジアセチルキトビオースデアセチラーゼ阻害剤及び新規化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016138075A JP2016138075A (ja) | 2016-08-04 |
JP6416001B2 true JP6416001B2 (ja) | 2018-10-31 |
Family
ID=56558862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015015146A Active JP6416001B2 (ja) | 2015-01-29 | 2015-01-29 | N,n’−ジアセチルキトビオースデアセチラーゼ阻害剤及び新規化合物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6416001B2 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001096529A2 (en) * | 2000-06-14 | 2001-12-20 | The Regents Of The University Of California, San Diego | Acetyl glucosaminyl inositol deacetylase, a mycothiol biosynthetic enzyme, and methods of use |
AU2002952121A0 (en) * | 2002-10-17 | 2002-10-31 | Alchemia Limited | Novel carbohydrate based anti-bacterials |
US8999954B2 (en) * | 2007-07-03 | 2015-04-07 | Childern's Hospital & Research Center at Oakland | Inhibitors of polysialic acid de-N-acetylase and methods for using the same |
-
2015
- 2015-01-29 JP JP2015015146A patent/JP6416001B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016138075A (ja) | 2016-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Westerik et al. | Aldehydes as inhibitors of papain | |
Ehmann et al. | Kinetics of avibactam inhibition against class A, C, and D β-lactamases | |
Blattler et al. | Stereochemical course of phosphokinases. The use of adenosine [. gamma.-(S)-16O, 17O, 18O] triphosphate and the mechanistic consequences for the reactions catalyzed by glycerol kinase, hexokinase, pyruvate kinase, and acetate kinase | |
JO2643B1 (en) | Derivatives of 2-aryl-6-phenylimidazole [a-1,2] pyridine, their preparation and therapeutic use | |
JP2013535220A5 (ja) | ||
Vašák et al. | Sodium and potassium ions in proteins and enzyme catalysis | |
UA89123C2 (ru) | Производные пиримидина для лечения абнормального роста клеток | |
Berlicki et al. | N-substituted aminomethanephosphonic and aminomethane-P-methylphosphinic acids as inhibitors of ureases | |
EA201190099A1 (ru) | (1-фенил-2-пиридин-4-ил)этиловые эфиры бензойной кислоты в качестве ингибиторов фосфодиэстеразы | |
NO20085169L (no) | Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes | |
US8129557B2 (en) | Phosphonic acid diester derivative and method for producing thereof | |
Tehrani et al. | Aminocarboxylic acids related to aspergillomarasmine A (AMA) and ethylenediamine-N, N′-disuccinic acid (EDDS) are strong zinc-binders and inhibitors of the metallo-beta-lactamase NDM-1 | |
TR200802703T2 (tr) | Büyümeyi ve/veya verimi arttırmak için prolinlerin kullanımı. | |
Koehler et al. | New, specific and reversible bifunctional alkylborinic acid inhibitor of acetylcholinesterase | |
WO2008152306A3 (fr) | Nouveaux substrats de peptidase | |
JP6416001B2 (ja) | N,n’−ジアセチルキトビオースデアセチラーゼ阻害剤及び新規化合物 | |
Khoma et al. | Synthesis, crystal structure, and spectral characteristics of N-(tert-butyl) aminomethanesulfonic acid | |
Rassukana et al. | A new strategy for asymmetric synthesis of aminophosphonic acid derivatives: the first enantioselective catalytic reduction of C-phosphorylated imines | |
Voráčová et al. | Harvesting phosphorus-containing moieties for their antibacterial effects | |
Siva Prasad et al. | Tween 20-/H2O promoted green synthesis, computational and antibacterial activity of amino acid substituted methylene bisphosphonates | |
Zhang et al. | Enzymatic synthesis of β-N-(γ-L (+)-glutamyl) phenylhydrazine with Escherichia coli γ-glutamyltranspeptidase | |
Eisenthal et al. | Activity of fluoro and deoxy analogues of glycerol as substrates and inhibitors of glycerol kinase | |
Asker et al. | Synthesis and biological evaluation of new quinazolinone derivatives | |
Morrison et al. | Inverse Acyl Phosph (on) ates: Substrates or Inhibitors of β-Lactam-Recognizing Enzymes? | |
US20220017480A1 (en) | Nonionic polyether surfactants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170914 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180713 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180925 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181003 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6416001 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |